Capecitabine-induced posterior reversible encephalopathy syndrome (PRES) in a patient with gastric adenocarcinoma.
Karim DiraniGeorgiana MaruscaJing WangDaniel JuzychPublished in: BMJ case reports (2023)
Posterior reversible encephalopathy syndrome (PRES) is characterised by encephalopathy, visual disturbances and seizures, accompanied by radiological parieto-occipital oedema. Immunosuppressive and immunomodulatory drugs are risk factors. While capecitabine-induced PRES cases are rare, this report details a young woman with advanced gastric adenocarcinoma on capecitabine. She exhibited symptoms of nausea, vomiting and abdominal pain before developing hypertension, drowsiness and a seizure. Brain MRI revealed parieto-occipital hyperintense areas indicative of PRES. Suspending capecitabine led to a gradually improved mental state. Prompt recognition and treatment of PRES offer reversibility, often achievable through dose reduction or discontinuation of the causative drug.
Keyphrases
- locally advanced
- abdominal pain
- phase ii study
- case report
- metastatic breast cancer
- early onset
- risk factors
- metastatic colorectal cancer
- squamous cell carcinoma
- rectal cancer
- high glucose
- phase iii
- drug induced
- diabetic rats
- blood pressure
- radiation therapy
- magnetic resonance imaging
- randomized controlled trial
- mental health
- single cell
- clinical trial
- middle aged
- endothelial cells
- depressive symptoms
- multiple sclerosis
- resting state
- combination therapy
- electronic health record
- cerebral ischemia
- replacement therapy
- subarachnoid hemorrhage